ArticleDrug design, development and therapy2017

Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor.

Wei-Wei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.